MEDICINES COMPANY, THE - THE MEDICINE COMPANY - ADVANCE THE DEVELOPMENT OF A PORTFOLIO OF ANTI-INFECTIVE PROGRAMS. IGF::OT::IGF
Key Details
Description
THE MEDICINE COMPANY - ADVANCE THE DEVELOPMENT OF A PORTFOLIO OF ANTI-INFECTIVE PROGRAMS. IGF::OT::IGF
Context & Analysis
On Feb 20, 2026, Department of Health and Human Services obligated $98,144,230 to MEDICINES COMPANY, THE for the medicine company - advance the development of a portfolio of anti-infective programs. igf::ot::igf. The award is classified under NAICS 541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY and issued as a cost sharing contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in PARSIPPANY, NJ. The contract is scheduled through Sep 30, 2030. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541711 — related awards are listed below.
Contractor Information
Similar Awards
CERUS - DEVELOPMENT AND IMPLEMENTATION OF PATHOGEN REDUCTION TECHNOLOGY (PRT). IGF::OT::IGF
CERUS CORPORATION
$185.5M
IGF::OT::IGF
JANSSEN VACCINES & PREVENTION B.V.
$48.9M
IGF::OT::IGF - DNAE / PATHOGEN IDENTIFICATION FROM SPECIMEN, VIA CAPTURE, EXTRACTION AND SEQUENCING (PISCES)
DNAE GROUP HOLDINGS LIMITED
$43.4M
AUTOGRAFT-SPARING PRODUCTS FOR DEFINITIVE CARE OF BURN INJURIES
AVITA MEDICAL AMERICAS, LLC
$40.8M
IGF::OT::IGF POINT OF CARE BIODOSIMETRY TEST
SRI INTERNATIONAL
$25.5M
Stay Updated
Get notified about new opportunities matching your interests.